BioMarin posted Q1 2026 EPS $0.76 vs $0.74 forecast and revenue $766 million vs $755.94 million expected.
Despite the beat, shares fell 1.52% in after‑hours trading, closing at $53.24.
Updated full‑year 2026 guidance projects revenue $3.825‑$3.925 billion (≈20% growth) and non‑GAAP EPS $4.85‑$5.05.
Amicus acquisition expected to be dilutive in 2026 but accretive from 2027, adding Galafold, Pombiliti and Opfolda.